JEFFREY W. CLARK
Physician in Providence, RI

License number
Rhode Island MD07387
Issued Date
Jul 9, 1988
Expiration Date
Jan 1, 1996
Category
Physician
Type
Allopathic Physician (MD)
Address
Address
Providence, RI
Education
Tufts University School of Medicine, Jan 6, 1978

Professional information

See more information about JEFFREY W. CLARK at trustoria.com
Jeffrey Clark Photo 1
English Teacher At Bishop Hendricken Hs

English Teacher At Bishop Hendricken Hs

Position:
English Teacher at Bishop Hendricken HS
Location:
Providence, Rhode Island Area
Industry:
Education Management
Work:
Bishop Hendricken HS - English Teacher
Education:
University of Vermont 1991 - 1995


Jeffrey Clark Photo 2
Treatment Of Tumorigenic Pathophysiological Conditions With Fgf-Cytoxic Conjugates

Treatment Of Tumorigenic Pathophysiological Conditions With Fgf-Cytoxic Conjugates

US Patent:
5478804, Dec 26, 1995
Filed:
May 26, 1994
Appl. No.:
8/250097
Inventors:
Paul Calabresi - Barrington RI
Julie G. Beitz - Rumford RI
Jeffrey W. Clark - Providence RI
A. Raymond Frackelton - Rumford RI
Douglas A. Lappi - Del Mar CA
Andrew J. Baird - San Diego CA
Assignee:
The Salk Institute for Biological Studies - San Diego CA
Roger Williams General Hospital - Providence RI
International Classification:
A61K 3818, A61K 3843
US Classification:
514 2
Abstract:
Conjugates comprising bFGF or other FGF polypeptides and a cytotoxic agent are prepared. The cytotoxic agent can be a ribosome-inactivating protein (RIP), such as saporin, which is attached to bFGF through a chemical bond, or the composition can be prepared as a recombinant DNA chimera. The conjugates are used to specifically target cells, in vivo and in vitro, which express FGF receptors. The cytotoxicity of the conjugates is proportional to the number of receptors expressed by a cell type. The conjugate is useful to effectively treat mammals, and in particular human patients, afflicted with tumorigenic conditions, such as human melanomas, human ovarian carcinomas, teratocarcinomas and neuroblastomas, and other FGF-mediated tumors caused by a proliferation of cells which express FGF receptors.